Tenax Therapeutics (TENX) Debt Ratio (2011 - 2023)

Tenax Therapeutics (TENX) reported Debt Ratio of 0.05 for Q3 2023, down 71.36% sequentially from 0.18 in Q4 2022.

Tenax Therapeutics (TENX) Debt Ratio (2011 - 2023) Analysis & Trends

Tenax Therapeutics (TENX) has 7 years of Debt Ratio data on file, last reported at 0.05 in Q3 2023.

For the quarter ending Q3 2023, Debt Ratio changed N/A year-over-year to 0.05; the trailing twelve-month figure through Sep 2023 stood at 0.05 (changed N/A YoY), and the FY2022 full-year result was 0.18, changed N/A from the prior year.
Debt Ratio declined to 0.05 in Q3 2023, from 0.18 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.18 in Q4 2022 to a low of 0.01 in Q1 2021.
A 4-year average of 0.05 and a median of 0.02 in 2020 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	1.41
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.11
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.05
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Tenax Therapeutics	67,856.40	67,856.40	-	-

Download Data